Authors: O. Chrapek; K. Špačková; J. Řehák Authors‘ workplace: Oční klinika FN a LF UP, Olomouc, přednosta doc. MUDr. Jiří Řehák, CSc. Published in: Čes. a slov. Oftal., , 2002, No. 6, p. 382-386 Category:
On a group of 13 eyes the authors evaluate their experience with medicamentoustreatment of central serous chorioretinopathy. For treatment they used the nonselectivebeta-blocker Trimepranol, 2x5mg/day. They found that in 11 eyes, in84.6 % cases, adherence of the ablated neuroepithelium of the macula occurredlatest within four months of treatment, in two eyes (15.4 %) this therapeutic dosedid not lead to remission of the disease even after four months of treatment andthe condition was evaluated as failure of treatment. The authors conclude thata therapeutic dose of Trimepranol of 2x5mg/day is not a reliable therapeuticsolution of central serous chorioretinopathy.
Key words: central serous chorioretinopathy - beta-blockers
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
